SARS-CoV-2 mRNA vaccination did not significantly increase most autoantibodies, but anti-DFS70 antibodies increased from 0.8% before to 5.1% at 7-9 months post-vaccination (p=0.001).
Observational (n=354)
Yes
Does SARS-CoV-2 mRNA vaccination increase the prevalence of autoantibodies in healthcare professionals?
SARS-CoV-2 mRNA vaccination does not significantly increase the prevalence of most autoantibodies, though an increase in anti-DFS70 antibodies and an association between severe vaccine adverse events and higher ANA titres were observed.
Absolute Event Rate: 5.1% vs 0.8%
p-value: p=0.001
The broad spectrum of interactions between autoimmune diseases and the SARS-CoV-2 vaccination is not fully understood. This study aims to evaluate the prevalence of anti-nuclear antibodies (ANA), anti-ENA, anticardiolipin antibodies (ACL), and anti-beta-2 glycoprotein I antibodies (anti-β2GPI) before and after the SARS-CoV-2 mRNA vaccination in a real-life setting in healthcare professionals. The identification of risk factors associated with vaccine immunogenicity was evaluated. The study group consisted of employees of two hospitals (354 individuals). Samples for antibody assays were collected before vaccination and at 7–9 months after complete immunisation. There was no significant increase in the prevalence of ANA, ACL or anti-β2GPI antibodies, or autoimmune diseases in subjects who were vaccinated 7–9 months after complete immunisation. In terms of detected anti-ENA, the anti-DFS70 antibodies were found in 6 times more subjects than before vaccination at the second blood draw (in 18 and 3 subjects, respectively) (p = 0.001). There were no significant relationships between a SARS-CoV-2 infection history, humoral response, cellular response, subject category, smoking, sex, body weight, ANA, anti-ENA, ACL, or anti-β2GPI. This study revealed a possible association between the severity of vaccine adverse events (VAEs) and ANA titre. Individuals with more severe VAEs (>10 points) after the second dose of the vaccine had significantly higher ANA titre after complete immunization. When analysing the significance of time between the ANA, anti-ENA, ACL, and anti- β2GPI assays and complete immunisation antibody values, no qualitative result was statistically significant. There was correlation between the time since complete immunization and ANA after.
Świerkot et al. (Mon,) conducted a observational in Autoimmunity development (n=354). SARS-CoV-2 mRNA vaccination vs. Before vaccination was evaluated on Prevalence of ANA, anti-ENA, ACL, and anti-β2GPI antibodies (p=0.001). SARS-CoV-2 mRNA vaccination did not significantly increase most autoantibodies, but anti-DFS70 antibodies increased from 0.8% before to 5.1% at 7-9 months post-vaccination (p=0.001).